Wechselwirkungen · Duavive
DUAVIVE 0.45 mg/20 mg modified-release tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-125225 · Präparat HOS-096029
Hormone contraceptives containing oestrogens have been shown to significantly decrease plasma concentrations of lamotrigine when co-administered due to induction of lamotrigine glucuronidation. This may reduce seizure control. Although the potential interaction between hormone replacement therapy and lamotrigine has not been studied, it is expected that a similar interaction exists, which may lead to a reduction in seizure control among women taking both medicinal products together.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-06T02:00:00Z · SHA-256 cebc18aeeaa7e87d26ff41a36f1789bee3f7e1eaa839d2f6fdebebc62c1ef614 · Passage 7c623f19c2d257327f427e0cb89a796b15ff89e9f36aaabbb2aa26a9cfb11d37 · Zeichen 1372–1859 im Abschnitt